Form 4: Alnylam Pharmaceuticals Director Acquires Stock Options

Alnylam Pharmaceuticals director Benjamin Cravatt acquired stock options valued at $295.63 per share, with vesting over three years.

Summary

• Benjamin Cravatt, a Director at Alnylam Pharmaceuticals, Inc., acquired stock options on June 1, 2026.
• The options have an exercise price of $295.63 per share.
• A total of 4,393 stock options were granted.
• These options will vest in three equal installments on the first, second, and third anniversaries of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation mechanism for a director rather than a significant new development or financial performance indicator.

Positives

• Director Benjamin Cravatt has acquired stock options, indicating a commitment to the company's future performance.
• The acquisition of options at a specific exercise price suggests a belief in the stock's potential to appreciate beyond that value.

Future Outlook

The stock options are exercisable and vest over a three-year period, with an expiration date in 2036, suggesting a long-term outlook for the company's performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry, aligning executive compensation with shareholder interests and incentivizing long-term value creation.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns management's interests with long-term shareholder value, provided the company's performance justifies the option's exercise.

Next Steps

• Vesting of stock options on the first, second, and third anniversaries of the grant date.

Key Dates

Keywords

Alnylam Pharmaceuticals, Form 4, Stock Options, Insider Trading, Director, Securities, Equity